Table 3 Effect of M3F on hematological parameters in PCM-treated mice.

From: Hepatoprotective potential of M3F, a benzimidazole pyrazole derivative, against paracetamol induced hepatotoxicity

Sample

RBC (106/μl)

Hb (g/dl)

Platelets (103/μl)

WBC (103/μl)

Vehicle control

10.90 ± 0.79

15.79 ± 0.41

901.2 ± 2s5.97

20 ± 1.30

PCM

6.82 ± 0.58##

11.27 ± 0.61###

598.2 ± 32.65###

29.2 ± 0.86###

SIL + PCM

10.78 ± 0.57**

14.77 ± 0.89**

784.6 ± 40.24**

22.2 ± 1.46**

M3F 100 μg/Kg + PCM

9.31 ± 0.70*

14.09 ± 0.62**

648.6 ± 27.42NS

23.2 ± 1.56**

M3F 200 μg/Kg + PCM

10.60 ± 0.55**

15.14 ± 0.84**

757.8 ± 32.88**

22 ± 2**

M3F 400 μg/Kg + PCM

10.43 ± 0.91**

15.80 ± 0.64***

796.6 ± 57.08**

21.8 ± 1.46**

  1. Each value represents mean ± S.E.M (n = 5), analyzed by One Way ANOVA using the LSD test for multiple comparisons. Level of significance is presented as *p < 0.05, **p < 0.01, ***p < 0.001 compared to PCM group and ###p < 0.001 compared to vehicle control group. Mice received a 7-day pretreatment with vehicle, silymarin, and M3F in respective groups. On day 8, hepatotoxicity was induced with PCM in all groups except vehicle control, and samples were collected 24 h post-PCM. Where Hb, Hemoglobin; M3F, test drug; PCM, Paracetamol; RBC, Red Blood Cells; SIL, Silymarin; WBC, White Blood Cells.
Back to article page